Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, announced today that its Symphony™ tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings," by Larry Greenemeier.
"Scientific American is one of the best known scientific trade journals and this article significantly raises the visibility of our Symphony tCGM System and the Prelude SkinPrep System for transdermal drug delivery within the scientific community and with the general public, including potential investors," commented Patrick T. Mooney, M.D., CEO and Chairman of the Board of Echo Therapeutics. "Prelude incorporates our patented skin permeation control feedback technology with a wireless, hand-held device. It is used to prepare a small area of the skin for the non-invasive biosensor and monitoring components of our Symphony tCGM System or for transdermal drug delivery. To date, we have had six consecutive positive pilot studies in glucose monitoring and our next generation skin preparation device incorporates substantial improvements beyond the prototype used in early studies. It represents one of the most important milestone events in the company's history and we anticipate that initial critical care and hospital market opportunities are greater than $1 billion. We welcome the exposure that the Scientific American article provides to our products, the hope it may give to diabetics and potential critical care users, and the progress we are making toward reaching our goals."